Premium
An in‐house‐anti‐hepatitis A virus (HAV)‐specific immunoglobulin M capture enzyme‐linked immunosorbent assay: Evaluation and application to an HAV outbreak
Author(s) -
Kiyohara Tomoko,
Ouchi Yoshimi,
Hasegawa Yoshiko,
Sato Tomoko,
Yoneyama Tetsuo,
Ishii Koji,
Ito Toshihiro,
Wakita Takaji
Publication year - 2009
Publication title -
journal of medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.782
H-Index - 121
eISSN - 1096-9071
pISSN - 0146-6615
DOI - 10.1002/jmv.21578
Subject(s) - virology , hepatitis a , outbreak , feces , hepatitis a virus , immunoglobulin m , antibody , biology , virus , immunoglobulin g , hepatitis , microbiology and biotechnology , immunology
An anti‐hepatitis A virus (HAV)‐specific immunoglobulin M capture enzyme‐linked immunosorbent assay (anti‐HAV IgM ELISA) kit was re‐designed for laboratory use and compared with a commercial anti‐HAV IgM detection system using 58 serum samples collected from patients, vaccines, and healthy individuals. Because concordance between the two systems was high (r = 0.93, P < 0.05), 19 sets of serum and fecal samples obtained from individuals exposed to an HAV outbreak were also examined. Serum levels of anti‐HAV IgM were determined using the in‐house ELISA kit and the HAV genome in fecal samples was detected using the polymerase chain reaction (PCR). Among the 19 sets of sample, 14 were positive for both anti‐HAV IgM and the HAV genome. All of those whose serum samples were anti‐HAV IgM negative were also negative for the HAV genome in fecal samples. The results of the in‐house IgM ELISA were consistent with those of the HAV genome detected by PCR and with the commercial IgM ELISA. The in‐house anti‐HAV IgM ELISA kit was therefore proven suitable for laboratory use and applicable to epidemiological studies of HAV infection. J. Med. Virol. 81:1513–1516, 2009. © 2009 Wiley‐Liss, Inc.